Drug development in systemic sclerosis: novel therapeutics to watch - PubMed
6 hours ago
- #immunotherapy
- #drug development
- #systemic sclerosis
- Systemic sclerosis (SSc) is understood as a triad of immune dysregulation, fibrosis, and vasculopathy.
- Recent drug development focuses on novel therapeutics targeting immune dysregulation, fibrosis, and vascular injury.
- Key advancements include cell-based immunotherapies, bispecific antibodies, and next-generation small molecules.
- Therapies now aim to modulate innate immunity directly, beyond adaptive immune targets.
- Successful disease modification requires synchronous interception of inflammation, fibrosis, and vascular injury.
- The review highlights pre-clinical and translational evidence shaping the SSc drug pipeline.